Partner Headlines - GSK

  1. The Internet Of Medical Things: 6 Stocks In Focus

    TalkMarkets
  2. Alphabet-Glaxo Joint Venture Targets 'Bioelectronics'

    Investors Business Daily
  3. Veeva Is Key Partner In Big Pharma's Race Against The Clock

    Investors Business Daily
  4. Stock Futures Up, Gaining Strength; Apple Hauls Techs Higher

    Investors Business Daily
  5. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  6. Getting to Know VBI Vaccines

    GuruFocus
  7. Brandes Makes a Variety of Reductions in 4th Quarter

    GuruFocus
  8. Stock Futures Up As Oil Behaves; Syngenta Up On ChemChina Deal

    IBD
  9. EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, ...

    Benzinga
  10. Benzinga's M&A Chatter for Thursday January 28, 2015

    Benzinga
  11. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  12. Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

    GuruFocus
  13. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  14. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  15. Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  16. Cisco Systems, Microsoft and Intel Bring High Dividend Yields ...

    GuruFocus
  17. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  18. High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox ...

    GuruFocus
  19. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  20. John Rogers' Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  21. 3 Global Investment Ideas From Gurus

    GuruFocus
  22. Relypsa Stock Jumps On Buyout Rumors

    IBD
  23. Skin Disease Drug Costs Jump

    IBD
  24. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD
  25. Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline

    GuruFocus
  26. 3 Investment Ideas of Ariel Investment's Rupal Bhansali

    GuruFocus
  27. Pfizer to Create a New Pharmaceutical Colossus

    GuruFocus
  28. GlaxoSmithKline

    IBD
  29. Gilead Beats Q3 Estimates As HIV Franchise Shines

    IBD
  30. ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase ...

    Benzinga
  31. Benzinga's Top Upgrades

    Benzinga
  32. IBM, Schlumberger PTs Lowered; Valeant Downgraded

    IBD
  33. GlaxoSmithKline Has a High (and Dangerous) Dividend Yield

    GuruFocus
  34. Tweedy Browne Global Value Adds to Stake in GlaxoSmithKline

    GuruFocus
  35. Liquidia Technologies And GlaxoSmithKline Advance Existing Collaboration; ...

    Benzinga
  36. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  37. Regulatory Update: GSK and Theravance Announce Intention to File ...

    GuruFocus
  38. Guru Stocks at 52-Week Lows: RDS.A, PTR, UL, BP, GSK

    GuruFocus
  39. Five Prime Therapeutics Announces Initial Data From Ongoing Phase ...

    Benzinga
  40. GSK and Theravance Announce Results From the SUMMIT COPD CV Survival ...

    GuruFocus
  41. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  42. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  43. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  44. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  45. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  46. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  47. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  48. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  49. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  50. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  51. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  52. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  53. Benzinga's Volume Movers

    Benzinga
  54. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  55. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  56. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  57. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  58. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  59. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  60. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  61. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  62. Axovant IPO Best In 20 Years

    IBD
  63. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  64. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  65. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  66. Perrigo buys Glaxo OTC drugs

    IBD
  67. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  68. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  69. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  70. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  71. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  72. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  73. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  74. Glaxo more bullish than Q1

    IBD
  75. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  76. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  77. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  78. GlaxoSmithKline

    IBD
  79. Novartis EPS beats the Street

    IBD
  80. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  81. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  82. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  83. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  84. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  85. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  86. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  87. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  88. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
  89. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  90. Can GlaxoSmithKline Continue Striving in the Face of World Challenges? ...

    GuruFocus
  91. GlaxoSmithKline Expands Its Portfolio Of Medicines In The US ...

    Benzinga
  92. Benzinga's Weekend M&A Chatter

    Benzinga
  93. Gilead Sciences Still has More Upside

    GuruFocus
  94. Johnson & Johnson Riding High On Ebola Vaccines

    GuruFocus
  95. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  96. Hot Biotech Stocks: Isis, Kite Jump On Big Deals

    IBD
  97. Isis Pharma To Develop GI Drugs With J&J

    IBD
  98. Pfizer, Home of Lipitor and Viagra, Lifts Dividend

    IBD
  99. Ebola Drug Work Continues

    IBD
  100. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD
Trading Center